A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Public ClinicalTrials.gov record NCT03321526. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram \[mg\] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an antidepressant drug in delaying time to all-cause discontinuation of study drug over a 6-months (24 weeks) treatment period, in participants with major depressive disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Study identification
- NCT ID
- NCT03321526
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Interventions
- JNJ-42847922 Drug
- Placebo Matching to JNJ-42847922 Drug
- Quetiapine XR Drug
- Placebo Matching to Quetiapine XR Drug
- Selective Serotonin Reuptake Inhibitor (SSRI) Drug
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2017 (Actual)
- Primary completion
- Jun 13, 2019 (Actual)
- Completion
- Jun 27, 2019 (Actual)
- Last update posted
- Apr 29, 2025
2017 – 2019
United States locations
- U.S. sites
- 50
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NoesisPharma Research | Phoenix | Arizona | 85032 | — |
| Clinical Research Consortium Arizona | Tempe | Arizona | 85283 | — |
| Woodland Research Northwest | Rogers | Arkansas | 72758 | — |
| Collaborative NeuroScience Network | Garden Grove | California | 92845 | — |
| Pacific Institute of Medical Sciences | Los Angeles | California | 90024 | — |
| National Research Institute | Los Angeles | California | 90057 | — |
| Excell Research Inc | Oceanside | California | 92056 | — |
| Desert Valley Research | Rancho Mirage | California | 92270 | — |
| Anderson Clinical Research | Redlands | California | 92374 | — |
| Artemis Institute for Clinical Research | San Diego | California | 92103 | — |
| Syrentis Clinical Research | Santa Ana | California | 92705 | — |
| Research Center for Clinical Studies, Inc. | Norwalk | Connecticut | 06851 | — |
| Clinical Research of South Florida | Coral Gables | Florida | 33134 | — |
| SIH Research | Kissimmee | Florida | 34759 | — |
| Premier Clinical Research | Miami | Florida | 33122 | — |
| Innova Clinical Trials | Miami | Florida | 33133 | — |
| Arocha Research Center Inc | Miami | Florida | 33145 | — |
| Suncoast Clinical Research | New Port Richey | Florida | 34652 | — |
| Stedman Clinical Trials | Tampa | Florida | 33613 | — |
| Northwest Behavioral Research Center | Marietta | Georgia | 30060 | — |
| Suburban Clinical Research Group, Inc | Bolingbrook | Illinois | 60490 | — |
| RxClinicals | Crystal Lake | Illinois | 60012 | — |
| Alexian Brothers Health System | Hoffman Estates | Illinois | 60169 | — |
| Psychiatric Medicine Associates LLC | Skokie | Illinois | 60076 | — |
| American Research, LLC | Jeffersonville | Indiana | 47130 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Phoenix Medical Research, Inc. | Prairie Village | Kansas | 66208 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21218 | — |
| BTC of New Bedford | New Bedford | Massachusetts | 02740 | — |
| Boston Clinical Trials & Medical Research | Roslindale | Massachusetts | 02135 | — |
| Rochester Center for Behavioral Medicine (RCBM) | Rochester Hills | Michigan | 48307 | — |
| Midwest Research Group | Saint Charles | Missouri | 63304 | — |
| PsychCare Consultants Research | St Louis | Missouri | 63128 | — |
| Clinical Research Consortium | Las Vegas | Nevada | 89119-5190 | — |
| SPRI Clinical Trials, LLC | Brooklyn | New York | 11235 | — |
| CNS Research Science, Inc. | Jamaica | New York | 11432 | — |
| Hapworth Psychiatric Medical PLLC | New York | New York | 10019 | — |
| Carolina Partners c/o Tripha Life Sciences | Raleigh | North Carolina | 27606 | — |
| Patient Priority Clinical Sites LLC | Cincinnati | Ohio | 45215 | — |
| Intend Research | Norman | Oklahoma | 73069 | — |
| IPS Research Company | Oklahoma City | Oklahoma | 73103 | — |
| Sooner Clinical Research | Oklahoma City | Oklahoma | 73112 | — |
| BTC Network | Lincoln | Rhode Island | 02865 | — |
| Hawkins Psychiatry, PC | Arlington | Texas | 76013 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Houston Endoscopy and Research Center, Inc. | Houston | Texas | 77079 | — |
| Texas Center for Drug Development Inc | Houston | Texas | 77081 | — |
| Pillar Clinical Research, LLC | Richardson | Texas | 75080 | — |
| Ericksen Research and Development | Clinton | Utah | 84015 | — |
| Northwest Clinical Research Center | Bellevue | Washington | 98004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03321526, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03321526 live on ClinicalTrials.gov.